SEC Form 4 · accession 0000899243-18-028967

AMEDISYS INC · AMED

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Table I — non-derivative securities

Table II — derivative securities

Explanation of responses

• F1The total amount of shares beneficially owned includes 887 shares held in an employee stock purchase plan account.
• F2The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.46 to $116.40, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
• F3The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
• F4The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.49 to $118.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
• F5The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.49 to $119.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
• F6The information in this report is based on a plan statement dated as of September 30, 2018.
• F7On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2015 were met, resulting in vesting of the option as to 5,625 shares (the "2015 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2015 Tranche Options vested on May 1, 2016, one-third of the 2015 Tranche Options vested on May 1, 2017 and one-third of the 2015 Tranche Options vested on May 1, 2018.
• F8On May 1, 2015, the reporting person was granted an option to purchase 22,500 shares of common stock. The option vests based on the Issuer's satisfaction of certain performance criteria for each of the fiscal years ending December 31, 2015, 2016, 2017 and 2018. The performance criteria for 2016 were met, resulting in vesting of the option as to 5,625 shares (the "2016 Tranche Options"), subject to additional time-based vesting as follows: one-third of the 2016 Tranche Options vested on May 1, 2017, one-third of the 2016 Tranche Options vested on May 1, 2018 and one-third of the 2016 Tranche Options will vest on May 1, 2019, provided that the reporting person remains continuously employed by the Issuer on such date, subject to pro-rated vesting provisions as provided in the award agreement for the stock option.